Three drugs based on AI-designed proteins have entered clinical trials in 2026, marking the convergence of artificial intelligence and synthetic biology as a practical therapeutic approach.
The proteins were designed using generative AI models similar to those used for text and image generation, but trained on protein structure databases. The AI can design proteins with specific functions — binding to disease targets, catalysing reactions, or modulating immune responses.
David Baker, who won the 2024 Nobel Prize in Chemistry for computational protein design, described the development as 'the beginning of a new era in medicine where we can design therapeutic molecules from scratch rather than discovering them in nature.'
The three drugs target: a rare metabolic disorder (Phase 1), a form of inflammatory bowel disease (Phase 1), and a specific cancer mutation (Phase 2). Results from the cancer trial are expected by late 2026.